IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats by unknown
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Background: HIV-associated sensory neuropathy affects over 50% of HIV patients and is a common peripheral
nerve complication of HIV infection and highly active antiretroviral therapy (HAART). Evidence shows that painful
HIV sensory neuropathy is influenced by neuroinflammatory events that include the proinflammatory molecules,
MAP Kinase, tumor necrosis factor-α (TNFα), stromal cell-derived factor 1-α (SDF1α), and C-X-C chemokine receptor
type 4 (CXCR4). However, the exact mechanisms of painful HIV sensory neuropathy are not known, which hinders
our ability to develop effective treatments. In this study, we investigated whether inhibition of proinflammatory
factors reduces the HIV-associated neuropathic pain state.
Results: Neuropathic pain was induced by peripheral HIV coat protein gp120 combined with 2′,3′-dideoxycytidine
(ddC, one of the nucleoside reverse transcriptase inhibitors (NRTIs)). Mechanical threshold was tested using von Frey
filament fibers. Non-replicating herpes simplex virus (HSV) vectors expressing interleukin 10 (IL10) were inoculated
into the hindpaws of rats. The expression of TNFα, SDF1α, and CXCR4 in the lumbar spinal cord and L4/5 dorsal
root ganglia (DRG) was examined using western blots. IL-10 expression mediated by the HSV vectors resulted in a
significant elevation of mechanical threshold. The anti-allodynic effect of IL-10 expression mediated by the HSV
vectors lasted more than 3 weeks. The area under the effect-time curves (AUC) in mechanical threshold in rats
inoculated with the HSV vectors expressing IL-10, was increased compared with the control vectors, indicating
antinociceptive effect of the IL-10 vectors. The HSV vectors expressing IL-10 also concomitantly reversed the
upregulation of p-p38, TNFα, SDF1α, and CXCR4 induced by gp120 in the lumbar spinal dorsal horn and/or the
DRG at 2 and/or 4 weeks.
Conclusion: The blocking of the signaling of these proinflammatory molecules is able to reduce HIV-related
neuropathic pain, which provide a novel mechanism-based approach to treating HIV-associated neuropathic pain
using gene therapy.
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In Europe and the U.S., approximately 2-7% of the
population suffers from neuropathic pain, a condition
caused by damage and/or inflammation to nerves fol-
lowing traumatic injury, viral infection or chemotherapy
[1]. Neuropathic pain (NP) related to human immuno-
deficiency virus-1 (HIV) infection is severe and unre-
lenting and represents an important unmet need in
medicine [2]. This HIV neuropathy can be associated
with viral infection alone, probably involving a role for
the envelope glycoprotein gp120 and/or antiretroviral
drug-induced toxic neuropathy associated with the use
of nucleoside analogue reverse transcriptase inhibitors
as a component of highly active anti-retroviral therapy
(HAART). Moreover, a growing body of evidence demon-
strates that proinflammatory mediators including tumor
necrosis factor alpha (TNFα) released by the activated
spinal glial cells and in the dorsal root ganglia (DRG),
are critical to enhancing pain [3-8]. Activation of p38
mitogen-activated protein kinase (MAPK) is known to
be important in cytokine regulation. The expression of
phospho-p38 (p-p38) in the DRG is well- characterized
following peripheral nerve injury associated with patho-
logical pain [9,10]. The C-X-C chemokine receptor
type 4 (CXCR4) acts as an important pro-inflammatory
factor in the neuropathogenesis of HIV/AIDS [11,12].
Furthermore, CXCR4 is required for gp120-induced cell
death [13]. Importantly, our studies and others show
that stromal cell-derived factor-1α (SDF1α) and its re-
ceptor CXCR4 are involved in the NP induced by gp120
[14] or ddC [15-17].
Interleukin 10 (IL-10) is an anti-inflammatory molecule
that has achieved interest as a therapeutic for neuropathic
pain. IL-10 blocks phosphorylation of MAPK pathways
[18], and suppresses the production and function of many
proinflammatory cytokines released by activated glia
[19,20]. IL-10 diminishes the levels of TNF mRNAs
after the onset of stimulation of polymorphonuclear
leukocytes (PMN) with lipopolysaccharide (LPS), a very
common proinflammatory inducer [21,22]. Lumbosa-
cral intrathecal administration of the IL-10 transgene or
protein leads to robust suppression of tactile allodynia
induced by sciatic nerve injury, as well as spinal inflam-
mation following a single intrathecal injection of gp120
protein [23-25]. Additionally, hyperalgesic responses to
TNFα or carrageenan are inhibited by intraplantar ad-
ministration of IL-10 (12).
While intrathecal IL-10 protein has been shown to
provide relief from pain in animal models, these effects
are short and closely parallel the half-life of IL-10 in the
cerebrospinal fluid (CSF) [25]. To provide prolonged
pain relief, gene therapy vectors encoding for the produc-
tion of IL-10 have been utilized [8,23,25]. The highly
replication-defective herpes simplex virus (HSV) genomicvectors can establish a persistent state that is used to
deliver and express transgenes in DRG neurons. DRG
neurons transduced with the HSV vector transport
transgene-coded enkephalin centrally in the bipolar
axon of the primary sensory afferents to the spinal dorsal
horn (SDH) [26]. Inoculation of the HSV vectors express-
ing the IL-10 gene significantly reduces mechanical allody-
nia below the level of injury after blunt trauma to the
spinal cord [27]. HIV neuropathic pain with a sizeable
morbidity is difficult to be treated in clinic [2]. In this
study, we tested the hypothesis that HSV vector-mediated
IL-10 expression could treat NP induced by HIV gp120
with antiretroviral drug. We found that this IL-10 gene
therapy produced the antinociceptive effects on NP in-
duced by the gp120 application with antiretroviral drug,
and reduced proinflammatory molecules p-p38, TNFα,
and CXCR4/SDF1α in the DRG and/or the SDH.
Results
The anti-allodynic effect of IL10 mediated by HSV vectors
in the gp120 +ddC model
Previous studies have demonstrated that the peripheral
gp120 application into the sciatic nerve, systemic ddC,
or combination of gp120 and ddC (gp120+ddC), results
in neuropathic pain characterized by mechanical allo-
dynia and upregulates TNFα [4,28-31]. The principal
anti-inflammatory activity of IL-10 is to inhibit the
production of proinflammatory cytokines [21]. We have
demonstrated that IL-10 mediated by the HSV vectors
reversed formalin-induced inflammatory pain [8]. Recent
studies show that animals inoculated with the HSV vectors
expressing IL10 reduces mechanical allodynia induced by
the spinal cord injury [27]. In this study, we further exam-
ined whether overexpression of IL-10 mediated by the
HSV vectors, reduced neuropathic pain induced by HIV
gp120 + ddC. HIV gp120 combined with ddC induced a
rapid decrease in mechanical threshold at 1 week. Sub-
cutaneous inoculation with QHIL10 (30 μl containing 1 ×
109 plaque-forming units/ml) or control vector Q0ZHG
was carried out in the plantar surface of the hind foot of
rats with neuropathic pain 1 week post application of
gp120 + ddC. QHIL10 resulted in a statistically significant
elevation of mechanical threshold that was apparent on
day 7 post vector inoculation compared with the control
vectors (F(1,12) = 11.996, P < 0.01, repeated measures
ANOVA, n = 7) (Figure 1A). The anti-allodynic effect of
the HSV vectors lasted for more than 3 weeks. For the
comparison of the differences at individual time points
between two groups, we used a two-tailed t test; there was
a significant difference at week 1, 2, and 3 between the
2 groups. The area under the effect-time curves (AUC)
after HSV in the QHIL10 group was significantly higher







































Figure 1 The anti-allodynic effect of IL-10 mediated by the HSV vectors on neuropathic pain induced by HIV gp120 combined with
ddC. (A) Mechanical allodynia in rats was shown 1 week post the gp120 application with ddC. The times of gp120 + ddC and HSV vector
inoculation were indicated by arrows. QHIL10 resulted in a statistically significant elevation of the mechanical threshold (g) compared with the
control vectors (F(1,12) = 11.996, P < 0.01, repeated measures ANOVA, n = 7). The comparison of differences at individual time points between two
groups was shown, *P < 0.05, **P < 0.01 vs. Q0ZHG, two-tailed t test. (B) The AUC in QHIL10 group was significantly higher than that in Q0ZHG,
***P < 0.001, t test, n = 7 rats).
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in the DRG and the SDH in the gp120 + ddC model
Activated MAP kinase p-p38 plays important role in the
maintenance of inflammatory/neuropathic pain [3,8,32].
In this study, we investigated whether the over-expression
of IL10 mediated by the HSV vectors reduced p-p38 in
the gp120 + ddC model. The L4/5 DRG and the SDH
were harvested on 2 weeks post vector injection. The
pooled L4/5 DRG and the SDH were used for western
blots. The data were presented as mean ± SEM and
were compared using one way ANOVA with a post hoc
PLSD test (StatView), n = 4 rats. In the DRG samples 2
weeks post vector injection, neuropathic rats inoculated
with Q0ZHG showed a statistically significant increase
in the expression of p-p38 compared with that in
the sham with Q0ZHG (P < 0.01 vs sham+ sal +Q0ZHG,
Figure 2A); the expression of p-p38 in neuropathic
rats with QHIL10 was markedly lower than that with
Q0ZHG (P < 0.05 vs gp120 + ddC +QOZHG, Figure 2A).
In the SDH samples 2 weeks post vector injection, the
expression of p-p38 in neuropathic rats with Q0ZHG
was markedly increased compared with that in sham
rats (P <0.01 vs sham + sal + Q0ZHG, Figure 2B); p-p38
in neuropathic rats with QHIL10 was lower than
that with Q0ZHG (P <0.01 vs gp120 + ddC +QOZHG,
Figure 2B).
Similarly, in a separate set of experiments, at 4 weeks
post vector injection, the L4/5 DRG and the SDH were
harvested for western blots. In the DRG, there was a sig-
nificant increase in p-p38 in neuropathic rats with
Q0ZHG compared with that in sham rats with Q0ZHG
(P <0.05 vs sham + sal + Q0ZHG, Figure 2C); the expres-
sion of p-p38 in neuropathic rats with QHIL10 was
significant lower than that in neuropathic rats withQ0ZHG (P <0.05 vs gp120 + ddC +QOZHG, Figure 2C).
In the SDH samples 4 weeks post vector injection,
p-p38 in neuropathic rats with Q0ZHG was markedly
increased compared with that in the sham group (P <0.01
vs sham+ sal +Q0ZHG, Figure 2D); in neuropathic rats
treated with QHIL10, p-p38 was lower than that with
Q0ZHG (P < 0.01 vs gp120 + ddC +Q0ZHG, Figure 2D).
The effect of HSV vectors over-expressing IL-10 on TNFα
in the DRG and the SDH in the gp120 + ddC model
Evidence shows that HIV gp120 or ddC mediated-
neuropathic pain increases TNFα in the spinal cord and
the DRG [4,14,30]. In the current study, we examined
whether overexpression of IL10 mediated by the HSV
vectors reduced TNFα in neuropathic pain induced by
gp120 + ddC. The L4/5 DRG and the SDH were har-
vested for western blots for full-length membrane
TNFα on 2 weeks post vector injection. The data were
presented as mean ± SEM, and were compared using
one way ANOVA with a post hoc PLSD test (StatView),
n = 4 rats. In the DRG, there was a marked increase in
TNFα in the gp120 + ddC + Q0ZHG group compared
with that in the sham group (P < 0.01 vs sham + sal +
Q0ZHG, Figure 3A); TNFα in the gp120 + ddC +
QHIL10 group, was significantly lower than that in the
gp120 + ddC + Q0ZHG group (P < 0.05, Figure 3A). In
the SDH, there was a marked increase in TNFα in
the gp120 + ddC + Q0ZHG group compared with that
in the sham group (P < 0.01, Figure 3B); TNFα expres-
sion in the gp120 + ddC + QHIL10 group was signifi-
cantly lower than that in the gp120 + ddC + Q0ZHG
(P < 0.01, Figure 3B).
In similar studies, at 4 weeks post vector injection, the
L4/5 DRG and the SDH were harvested for western
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Figure 2 The effect of IL-10 mediated by the HSV vectors on the expression of p-p38 in the DRG and the SDH at 2 or 4 weeks. Rats
with neuropathic pain were inoculated with QHIL10 or Q0ZHG 1 week post gp120 application with ddC. In the control group, rats received the
sham surgery with saline IP injection and Q0ZHG (sham + sal + Q0ZHG). (A and B) Two weeks post vector injection, the L4/5 DRG (A) and the
SDH (B) were harvested, and the expression of p-p38 was tested using western blots. The data were analyzed using one way ANOVA with post
hoc PLSD test, mean ± SEM, **P < 0.01 vs. control group, # P < 0.05, ## P < 0.01 vs gp120 + ddC + Q0ZHG, n = 4 rats. (C and D) Four weeks post
vector injection, the L4/5 DRG (C) and the SDH (D) were harvested, and the expression of p-p38 was tested using western blots. The data were
analyzed using one way ANOVA with post hoc PLSD test, mean ± SEM, *P < 0.05, **P < 0.01 vs. control, # P < 0.05, ## P < 0.01 vs gp120 + ddC +
Q0ZHG, n = 4 rats.
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TNFα in the group of gp120 + ddC +Q0ZHG compared
with that in the sham group (P <0.05, Figure 3C);
the increased TNFα was reversed by treatment
with QHIL10 in the DRG (P <0.05, Figure 3C). In
the SDH samples 4 weeks post vector injection,
there was a marked increase in TNFα in gp120 +
ddC + Q0ZHG group compared with that in sham
group, however, there was no significant difference
between gp120 + ddC + Q0ZHG group and gp120 +
ddC + QHIL10 group (Figure 3D).The effect of HSV vectors over-expressing IL-10 on SDF1α
in the DRG and the SDH in the gp120 + ddC model
TNFα enhances the expression of CXCR4, which facili-
tates the chemotactic invasiveness of the cultured human
mesenchymal stem cells toward SDF1α [33]. We have re-
ported that IL-10 is able to suppress overexpression of
mRNA and protein of TNFα induced by formalin into the
hindpaws [8]. However, it is not known if IL10 reduced
production of SDF1α in vivo in the gp120 + ddC-induced
neuropathic pain state. In this study, we investigated
whether the overexpression of IL10 mediated by the HSV
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Figure 3 The effect of IL-10 mediated by the HSV vectors on the expression of TNFα in the DRG and the SDH at 2 or 4 weeks. Rats with
neuropathic pain were inoculated with QHIL10 or Q0ZHG 1 week post gp120 with ddC. In the control group, rats received the sham surgery with
saline IP injection and Q0ZHG (sham + sal + Q0ZHG). The data were analyzed using one way ANOVA with post hoc PLSD test, mean ± SEM. (A and B)
Two weeks post vector injection, the L4/5 DRG (A) and the SDH (B) were harvested, and the expression of TNFα was tested using western
blots. ** P < 0.01 vs. control, # P < 0.05, ## P < 0.01 vs gp120 + ddC + Q0ZHG, n = 4 rats. (C and D) Four weeks post vector injection, the L4/5
DRG (C) and the SDH (D) were harvested, and the expression of TNFα was tested using western blots. *P < 0.05 vs. control, # P < 0.05 vs gp120 +
ddC +Q0ZHG, n = 4 rats.
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In the DRG samples 2 weeks post vector injection,
there was a significant increase in SDF1α in neuro-
pathic rats with Q0ZHG compared with that in sham
rats (P < 0.01, Figure 4A); the expression of SDF1α in
the DRG in neuropathic rats with QHIL10, was mark-
edly lower than that in neuropathic rats with Q0ZHG
(P < 0.05, Figure 4A). In the SDH samples 2 weeks post
vector injection, there was a significant increase inSDF1α in neuropathic rats with Q0ZHG compared
with that in the sham rats (P < 0.01, Figure 4B); expres-
sion of SDF1α in neuropathic rats treated with QHIL10
was markedly lower than that in neuropathic rats with
Q0ZHG (P < 0.01, Figure 4B).
In the DRG 4 weeks post vector injection, there was no
significant increase in SDF1α in neuropathic rats with
Q0ZHG compared with that in the sham rats (Figure 4C),
however, the expression of SDF1α in neuropathic rats
01























   



















































































































Figure 4 The effect of IL-10 mediated by HSV vectors on the expression of SDF1α in the DRG and the spinal cord at 2 or 4 weeks. Rats
with neuropathic pain were inoculated with QHIL10 or Q0ZHG 1 week post gp120 with ddC. In the control group, rats received the sham surgery
with saline IP injection and Q0ZHG (sham + sal + Q0ZHG). The data were analyzed using one way ANOVA with post hoc PLSD test, mean ± SEM.
(A and B) Two weeks post vector injection, the L4/5 DRG (A) and the SDH (B) were harvested, and the expression of SDF1α was tested using
western blots. ** P < 0.01 vs. control, # P < 0.05, ## P < 0.01 vs gp120 + ddC + Q0ZHG, n = 4 rats. (C and D) Four weeks post vector injection, the
L4/5 DRG (C) and the SDH (D) were harvested, and the expression of SDF1α was tested using western blots. # P < 0.05 vs. gp120 + ddC + Q0ZHG,
n = 4 rats.
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rats with Q0ZHG (P < 0.05, Figure 4C). In the SDH
samples 4 weeks post vector injection, neuropathic
rats with Q0ZHG showed a statistically insignificant
increase in the expression of SDF1α compared with
sham rats (P = 0.07, Figure 4D); the expression of
SDF1α in neuropathic rats treated with QHIL10, was
markedly lower than that in neuropathic rats with
Q0ZHG (P <0.05, Figure 4D).The effect of the HSV vectors over-expressing IL-10 on
CXCR4 in the DRG and the SDH in the gp120 + ddC model
In the DRG 2 weeks post vector injection, neuropathic
rats inoculated with Q0ZHG showed a statistically sig-
nificant increase in CXCR4 compared with the sham
(P < 0.01, Figure 5A); the expression of CXCR4 in neuro-
pathic rats with QHIL10, was significantly lower than that
in neuropathic rats with Q0ZHG (P < 0.01, Figure 5B).
In the SDH, there was a significant increase in CXCR4
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Figure 5 The effect of IL-10 mediated by the HSV vectors on the expression of CXCR4 in the DRG and the spinal cord at 2 or 4 weeks.
Rats with neuropathic pain were inoculated with QHIL10 or Q0ZHG 1 week post gp120 with ddC. In the control group, rats received the sham
surgery with saline IP injection and Q0ZHG (sham + sal + Q0ZHG). The data were analyzed using one way ANOVA with post hoc PLSD test,
mean ± SEM. (A and B) Two weeks post vector injection, the L4/5 DRG (A) and the SDH (B) were harvested, and the expression of CXCR4 was
tested using western blots. **P < 0.01 vs. control, ## P < 0.01 vs gp120 + ddC + Q0ZHG, n = 4 rats. (C and D) Four weeks post vector injection, the
L4/5 DRG (C) and the SDH (D) were harvested, and the expression of CXCR4 was tested using western blots. *P < 0.05 vs control, ## P < 0.01 vs.
gp120 + ddC + Q0ZHG, n = 4 rats.
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rats (P < 0.01, Figure 5B); CXCR4 in neuropathic rats
with QHIL10, was markedly lower than that in neuro-
pathic rats with Q0ZHG (P < 0.01, Figure 5B).
In the DRG 4 weeks post vector injection, CXCR4 was
significantly higher in neuropathic pain rats with Q0ZHGthan that in sham rats (P < 0.05 vs sham+ sal +Q0ZHG,
Figure 5C); the increased expression of CXCR4 in
neuropathic rats with QHIL10, was lower than that with
Q0ZHG (P < 0.01 vs gp120 + ddC + Q0ZHG, Figure 5C).
There was no significant difference in neuropathic rats
with Q0ZHG compared with either sham rats or
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samples at 4 weeks after vector injection.
Discussion
The chronic nature of neuropathic pain can dramatically
reduce productivity and quality of life, and is notoriously
difficult to manage using currently available therapeutic
regimens. The principal immunomodulatory activity of
IL-10 is to inhibit the production of proinflammatory
cytokines [21]. We have previously demonstrated that
IL-10 mediated by the HSV vectors reversed formalin-
induced inflammatory pain [8]. Recent studies show
that animals inoculated with the HSV vectors express-
ing IL10 reduces mechanical allodynia induced by the
spinal cord injury [27]. Previous studies have also dem-
onstrated that the application of gp120 onto sciatic
nerve, systemic ddC, or the combination of these treat-
ments, resulted in NP characterized by mechanical allo-
dynia and upregulation of inflammatory factors in the
spinal cord and/or the DRG [4,15,29-31]. Moreover, these
effects can be inhibited by intrathecal anti-inflammatory
chemicals or by HSV-mediated TNF soluble receptor
[14,17]. The current study demonstrates that gp120 com-
bined with ddC induced neuropathic pain, and that IL-10
mediated by the HSV vectors resulted in a significant
elevation of mechanical threshold that was apparent
one week post vector inoculation. Specifically, AUC of
the mechanical threshold response in the HSV vectors
expressing IL-10 was increased compared with the
control vectors, indicating the markedly anti-allodynic
effect of IL-10. The HSV vectors expressing IL-10 re-
versed the upregulation of p-p38, TNFα, SDF1α, and
CXCR4 induced by gp120 with ddC in the lumbar SDH
and the DRG at 2 and/or 4 weeks.
MAPKs such as p38 are important for intracellular
signal transduction and play critical roles in regulating
neural plasticity and inflammatory responses [34]. The
signaling of p38 is critical upon exposure to HIV gp120
for the neurotoxic phenotype of monocytic cells [35,36].
In in vivo studies, Milligan and colleague have reported
that the systemic p38 inhibitor CNI-1493 blocks intra-
thecal gp120-induced mechanical allodynia [37]. Our
unpublished data show that systemic ddC induced the
upregulation of p-p38 in the spinal cord dorsal horn and
the DRG.
HIV virus infection is able to increase the production
of several cytokines [38]. It is reported that there is an
increased level of TNFα in the CSF [39], blood plasma
[40], spinal cord [41], and brain [42] in patients with
HIV. We and others have reported that the application
of the recombinant gp120 to the sciatic nerve increases
TNFα in the DRG and the spinal cord [4,28]. Further-
more, intrathecal TNFα siRNA or TNF soluble recep-
tor (TNFSR) reduces the gp120 application-inducedmechanical allodynia, indicating that TNFα in the
spinal cord and/or the DRG are involved in neuro-
pathic pain induced by HIV gp120 [4]. TNF soluble re-
ceptor mediated by the HSV vectors suppresses gp120-
induced neuropathic pain and reduces TNFα [14].
Taken together, these data highlight the importance of
TNFα in the development of the exaggerated pain state
related to HIV gp120.
HAART has dramatically reduced the HIV/AIDS as-
sociated morbidity and mortality [43]. Although the
incidence of most neurological complications of HIV
has fallen with HAART, rate of HIV-SN has been rising
[44]. One of the reasons is that NRTIs are neurotoxic and
can cause a dose-dependent painful peripheral neuropathy
[45]. Our previous studies demonstrate that TNFα is in-
volved in the mechanisms of ddC-induced neuropathic
pain [30]. Knockdown of TNFα with siRNA blocks the
mechanical allodynia induced by ddC; intrathecal adminis-
tration of recombinant TNFSR, reverses mechanical allo-
dynia induced by ddC, suggesting that TNFα is involved
in ddC-induced neuropathic pain [30]. Using HSV vectors
expressing TNFSR, we extended our previous studies
and found that it suppressed mechanical allodynia and
decreased TNFα induced by ddC [17].
Evidence shows that chemokines and their receptors
play an important role in inducing and maintaining
neuropathic pain [14-16]. Chemokine receptors, in par-
ticular CXCR4 and CCR5, mediate HIV infection of
immunocompetent cells as well as microglia [11]. The
interplay of TNFα and HIV-1 leads to the enhanced ex-
pression of toxic chemokines [46]. CXCR4 and its ligand
SDF1α are important factors in the neuropathogenesis
of HIV/AIDS [11]. HIV gp120 may bind to and activate
CXCR4 expressed in the DRG neurons in a CD-4-
independent manner [47,48], suggesting the direct neuro-
toxic effects of gp120 on the neurons [49]. Our recent
studies have shown that HIV gp120 induces the upregula-
tion of SDF1 and CXCR4 in the spinal cord and the DRG
[14]. White and colleagues reported that systemic ddC in-
duces the expression of CXCR4 mRNA in glia and neu-
rons, and SDF1 mRNA in glia [15]. Pain hypersensitivity
produced by ddC is inhibited by systemic CXCR4 antag-
onist, AMD3100, suggesting that NRTIs produce painful
hypersensitivity through the CXCR4 signaling in the DRG
[15]. We report that ddC induces the overexpression of
SDF1α and CXCR4 in the protein level in the spinal cord
and the DRG, and that intrathecal administration of
AMD3100 reverses the mechanical allodynia induced by
ddC [17]. In in vitro studies, SDF1 is produced under the
control of inflammatory factors, such as TNFα [50]. TNFα
significantly enhances expression of CXCR4, which facili-
tates the chemotactic invasiveness of human mesenchymal
stem cells toward SDF1α [33]. Our studies demonstrate
that blockage of TNFα by HSV-mediated TNFSR reverses
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that SDF1α/CXCR4 system is involved in the mecha-
nisms of TNFα in neuropathic pain induced by gp120
or ddC [14,17].
IL-10 inhibits the production of proinflammatory cyto-
kines [21,22]. In the in vitro studies, IL-10 diminishes
TNF mRNA after the onset of stimulation of polymorpho-
nuclear leukocytes with LPS, identifying the biological ac-
tion of IL-10 as a suppressor of the inflammatory response
[21]. We have shown that IL-10 reduces the p-p38 and de-
creases the expression of full-length membrane spanning
TNFα following lipopolysaccharide stimulation of micro-
glia in vitro; IL-10 also reduces intracellular cleavage of
membrane TNFα [8]. Hypoxia-mediated increases in
CXCR4 expression and cell survival are lower in IL-10-
deficient othelial progenitor cell [51]. IL-10 also downre-
gulates CXCR4 mRNA expression in CD4+ T lymphocytes
[52]. In the in vivo studies, IL-10 inhibits the writhing
response induced by acetic acid or zymosan in mice,
and the knee joint incapacitation induced by zymosan
in rats; IL-10 inhibits the release of TNFα from mice
peritoneal macrophages obtained after local injection of
zymosan [53]. Acute intrathecal administration of rat
IL-10 protein itself briefly reverses CCI-induced mech-
anical allodynia [54]. Hyperalgesic responses to TNFα
or carrageenan are inhibited by intraplantar administra-
tion of IL-10 [55]. In the present studies, we report for
the first time that IL-10 suppresses TNFα and SDF1/
CXCR4 in the neuropathic pain state induced by gp120
with ddC.
To produce a long-term analgesic effect, non-viral
plasmids or viral vectors expressing IL-10 may repre-
sent a promising approach in a variety of pain states.
Intrathecal delivery of plasmid DNA encoding IL-10
gene prevents, and progressively reverses the allodynic
state induced by paclitaxel (a chemotherapy drug), and
markedly decreases paclitaxel-induced expression of
TNF mRNA in the lumbar DRG [56]. Repeated intra-
thecal delivery of the plasmid DNA vectors encoding
IL-10 gene abolishes neuropathic pain induced by sci-
atic chronic constriction injury (CCI) [23]. Adenoviral
vectors encoding human IL-10 gene prevent and reverse
thermal hyperalgesia and mechanical allodynia in the
CCI model [54]. Gene transfer to the primary sensory
neurons of the DRG with self-complementary recombin-
ant adeno-associated virus serotype 8 expressing IL-10,
leads to significant reversal of mechanical allodynia in
chronic neuropathic pain induced by L5 spinal nerve
ligation [57]. We have found that transduction of the
DRG neurons in vivo achieved by subcutaneous inocu-
lation of the HSV vectors in the foot results in produc-
tion of transgene-coded IL-10 in the DRG neurons and
transport of the gene product to terminals in the spinal
cord, suppresses the formalin-induced nociceptive effectand reduces TNFα and p-p38 expression [8]. IL-10 me-
diated by HSV almost totally reversed the upregulation
of mRNA of TNFα in the spinal cord in the formalin
pain model [8]. Recent studies show that animals inocu-
lated with the HSV vectors expressing IL10 reduces
mechanical allodynia induced by the spinal cord injury,
which correlates with a significant decrease in spinal
TNFα [27]. In the current studies, we extend our previ-
ous results showing that IL-10 expressed by the HSV
vectors reduced neuropathic pain induced by HIV
gp120 combined with ddC, and reversed the upregulation
of p-p38, TNFα, SDF1α, and CXCR4 in the neuropathic
state in the lumbar SDH and the DRG at 2 and/or 4 weeks.
The mechanisms by which IL-10 reduces neuropathic pain
are not clear. Previous studies suggest that TNFα medi-
ated SDF1α/ CXCR4 pathway in the gp120 and ddC in-
duced neuropathic pain models [14,17]. It is possible that
in this study, IL-10 suppressed SDF1α/ CXCR4 through
reduced TNFα signaling in the gp120 combined with ddC
state. Local application of gp120 to sciatic nerve induces
wide neurochemical changes in both the DRG and the
spinal cord. Meanwhile, IL-10 mediated by HSV reduced
those inflammatory factors in both the DRG and the
spinal cord. It is possible that IL10 may protect against
HIV-induced pain by preserving integrity of gene ex-
pression in DRG and thus preventing abnormal release
of nociceptive peptides from DRG neurons into the dor-
sal horn. Future work will study the exact molecular
mechanisms/pathways by which IL-10 suppresses those
inflammatory factors.
Methods
A non-replicating HSV-based vectors expressing IL10
The construction of HSV vectors expressing IL10 has been
described (designated in that report as QHIL10) [58].
QHIL10 contains the full-length rat IL10 gene tagged with
hemagglutinin (HA) under the control of the human cyto-
megalovirus immediate-early promoter (HCMC IEp); the
control vectors contains the lacZ gene (Q0ZHG) in place
of IL10-HA [27]. In our previous studies, we demonstrated
that the vectors produce IL10 from the primary DRG
neurons infected in vitro and in the spinal cord in vivo
[8]. The investigators of vector injection were blinded
for behavior testing.
Animals
Male Sprague-Dawley rats weighing 225 to 250 g were
housed 1 to 3 per cage approximately 7 days prior to
the beginning of the study. Rats were maintained with
free access to food and water and were on a 12:12, light:
dark schedule at 21°C and 60% humidity. All housing
conditions and experimental procedures were approved
by the University Animal Care and Use Committee
at the University of Miami, FL., and were conducted in
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Model of neuropathic pain induced by HIV gp120
combined with systemic ddC
Under 1-2% isoflurane anesthesia and aseptic surgical
conditions, the left sciatic nerve of rats was exposed in
the popliteal fossa without damaging the perineurium.
The sciatic nerve was wrapped loosely, with a strip of
oxidized regenerated cellulose (Surgicell, Ethicon), previ-
ously soaked in 200 μl of a 0.1% rat serum albumin
(RSA) in saline solution, containing 40 ng of gp120-MN
(Immunodiagnostics, Bedford, MA). The procedure was
performed on sham-operated animals but without appli-
cation of gp120 as previously reported [14,28]. The
nerve was gently manipulated back into place and inci-
sions of skin closed with staples. Rats were injected with
1 ml of ddC (20 mg/kg, IP) [31] at the time of applica-
tion of perineural gp120 (henceforth referred to as
gp120 + ddC) as previously reported [29]. Sham controls
were treated with perineural RSA and IP saline in the
same regime as perineural gp120 and systemic ddC
treatment.
Mechanical threshold
Animals were placed in non-transparent plastic cubicles
on a mesh floor for an acclimatization period of at least
30 min on the morning of the test day. Mechanical
threshold was determined by assessing paw withdrawal
to von Frey filaments (Stoelting, Wood Dale, IL) of graded
tensile strength. A series of calibrated von Frey filaments
were presented serially to the hind paw in ascending order
of strength, with each filament applied for 6 s with suffi-
cient force to cause slight bending against the paw. A posi-
tive response was defined as a rapid withdrawal and/or
licking of the paw immediately on application of the
stimulus. Whenever a positive response to a stimulus
occurred, the next smaller von Frey hair was applied,
and whenever a negative response occurred, the next
higher force was applied. In the absence of a response at
a pressure of 15.1 g, animals were assigned to this cutoff
value. The tactile stimulus producing a 50% likelihood
of withdrawal was determined using the up-and-down
method [3].
Western blots
Under deep anesthesia, the L4-5 DRG or the spinal
cord was removed rapidly, frozen on dry ice, and stored
at -80°C. These tissues of the spinal dorsal horn dis-
sected following the spinal cord samples were homoge-
nized in protein lysis buffer (150 mM sodium chloride,
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0) containing protease inhibitors and
phosphatase inhibitors (Phosphatase Inhibitor Cocktails1/2). The homogenate was centrifuged at 18,000 g for
20 min at 4°C. The supernatant was collected and assayed
for protein concentration using the DC protein assay
(Bio-Rad). Aliquots containing 30 μg of protein were
dissolved in Laemmli buffer and denatured at 95°C for
5 min; the proteins were separated by 10% Tris-glycine
SDS-PAGE gel and transferred to a PVDF membrane.
The membranes were blocked with 5% nonfat dry milk
in PBS buffer, and then incubated with primary anti-
bodies overnight at 4°C, including rabbit anti-p-p38
(1:1000, Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit polyclonal anti-TNFα (1 : 500, Chemicon, Temecula,
CA), goat anti-CXCR4 (1:1000, Santa Cruz Biotechnology),
rabbit anti-SDF1a (1:500, ABCAM, Cambridge, MA),
and mouse anti-β-actin (1 : 8000, Sigma). The blots
were incubated with secondary antibodies (Santa Cruz
Biotechnology), and developed in chemiluminescence
solution (Pierce Biotechnology). Quantification of Western
blots was done from the obtained chemiluminescence
values (BioRad ChemiDoc). Target protein bands were
normalized using the amount of β-actin.
Data analysis
The statistical significance of the differences of neurochem-
ical changes was determined by the t test or one-way
ANOVA post-hoc test following Fisher’s PLSD (StatView5).
To compare the difference between the time-course curves
of the behavioral testing we used repeated measures
ANOVA with one within-subjects factor (time) and one
between-subjects factor (group) of a General Linear Model
(IBM, SPSS21). All data were presented as mean ± SEM,
and P-values of less than 0.05 were considered to be
statistically significant.
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